Home Newsfeeds Needham Reiterates Buy on Alkami Technology, Maintains $20 Price Target

Needham Reiterates Buy on Alkami Technology, Maintains $20 Price Target

Needham analyst Mayank Tandon reiterates Alkami Technology (NASDAQ:ALKT) with a Buy and maintains $20 price target.

byBenzinga Newsdesk

February 24, 2023

1 minute read

Needham analyst Mayank Tandon reiterates Alkami Technology (NASDAQ:ALKT) with a Buy and maintains $20 price target.

CVS Health’s Q4 Earnings Relieve Investor Concerns But Lowers 2024 Profit Guidance Citing Elevated Medical Cost Trends

By Vandana Singh

February 7, 11:58 AM

CVS Health beats Q4 expectations with $2.12 adjusted EPS, allays concerns over healthcare costs. Sales rise 11.9% to $93.81 billion.

CVS

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

By Vandana Singh

February 21, 8:41 AM

The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…

CSLLY

Keybanc Maintains Overweight on Purple Innovation, Raises Price Target to $8

By Benzinga Newsdesk

February 1, 5:39 AM

Keybanc analyst Bradley Thomas maintains Purple Innovation (NASDAQ:PRPL) with a Overweight and raises the price target from $7 to $8.

PRPL

Analyst Ratings

Analyst Expectations for Victoria’s Secret’s Future

By Benzinga Insights

August 25, 10:00 AM

Within the last quarter, Victoria’s Secret (NYSE:VSCO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

VSCO

Needham Reiterates Buy on Alkami Technology, Maintains $20 Price Target

Related Posts

CVS Health’s Q4 Earnings Relieve Investor Concerns But Lowers 2024 Profit Guidance Citing Elevated Medical Cost Trends

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

Keybanc Maintains Overweight on Purple Innovation, Raises Price Target to $8

Analyst Expectations for Victoria’s Secret’s Future